Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Non-cash Items (2016 - 2025)

Historic Non-cash Items for Celldex Therapeutics (CLDX) over the last 14 years, with Q3 2025 value amounting to $72.8 million.

  • Celldex Therapeutics' Non-cash Items fell 1475.41% to $72.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.8 million, marking a year-over-year decrease of 1475.41%. This contributed to the annual value of $4.0 million for FY2024, which is 9596.29% down from last year.
  • As of Q3 2025, Celldex Therapeutics' Non-cash Items stood at $72.8 million, which was down 1475.41% from $81.9 million recorded in Q2 2025.
  • In the past 5 years, Celldex Therapeutics' Non-cash Items ranged from a high of $122.6 million in Q4 2022 and a low of $4.0 million during Q4 2024
  • For the 5-year period, Celldex Therapeutics' Non-cash Items averaged around $60.7 million, with its median value being $67.1 million (2025).
  • In the last 5 years, Celldex Therapeutics' Non-cash Items surged by 428203.03% in 2021 and then crashed by 9596.29% in 2024.
  • Over the past 5 years, Celldex Therapeutics' Non-cash Items (Quarter) stood at $84.7 million in 2021, then skyrocketed by 44.75% to $122.6 million in 2022, then dropped by 19.58% to $98.6 million in 2023, then crashed by 95.96% to $4.0 million in 2024, then soared by 1728.89% to $72.8 million in 2025.
  • Its last three reported values are $72.8 million in Q3 2025, $81.9 million for Q2 2025, and $67.1 million during Q1 2025.